MarketCatalyst
← Back to Resources
Earnings

Sanmina Beats Fiscal Q4 2026 Estimates as Revenue Rises 84% to $3.86B

Revenue of $3.86B vs. $3.48B expected and adjusted EPS of $4.43 vs. $3.27; revenue up 84% from a year earlier.

Published Nov 9, 2026 · 4:02 PM ET · 2 min read

Sanmina (SANM) beat estimates for the fiscal fourth quarter of 2026 on both revenue and adjusted EPS. Revenue was $3.86 billion, up 84% from a year earlier, above the $3.48 billion estimate, and adjusted EPS was $4.43, up 165% from a year earlier, above the $3.27 estimate.

Shares fell 0.0% in after-hours trading as of 4:00 p.m. ET, to $149.64 from a $149.69 close.

$4.43
Adjusted EPS, up 165% YoY vs. $3.27 estimate
$3.86B
Revenue, up 84% YoY vs. $3.48B estimate
-0.0%
Shares after hours as of 4:00 p.m. ET

Fiscal Q4 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS$3.27$4.43Beat by 35%
Revenue$3.48B$3.86BBeat by 11%
ChangeYoYQoQ
Adjusted EPS▲ 165%▲ 34%
Revenue▲ 84%▲ 11%

By our calculation, revenue was $380.4 million above the estimate and adjusted EPS was $1.16 above it. The QoQ column compares with the previous quarter's revenue of $3.46 billion and adjusted EPS of $3.31. The YoY column compares with $2.10 billion and $1.67 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 8 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 8 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $2.10 billion, $3.19 billion, $4.01 billion, $3.46 billion and $3.86 billion.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of $2.82 and revenue of $3.42 billion next quarter, based on 3 analysts.
  • Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 84% increase to $3.86 billion.
  • Estimate record. Whether Sanmina extends a record of beating EPS estimates in 8 of its last 8 reports.
  • Related coverage. See our reports on Global Ship Lease, KKR &, Turning Point Brands and ImmunityBio.

Sources: Results are from Sanmina's Nov. 9, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Sanmina's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.